Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Industry News

Respiratory bacterial panel gets CE-IVD mark

Feb. 28, 2018—ElitechGroup Molecular Diagnostics launched its Respiratory Bacterial Elite MGB Panel, a high-performance multiplex assay for the diagnosis of bacterial respiratory infections and validated with the Elite InGenius fully automated sample-to-result system. The panel detects and differentiates in a single reaction M. pneumoniae, C. pneumoniae, and L. pneumophila. A clinical study has demonstrated a performance of 100 percent diagnostic sensitivity and 100 percent diagnostic specificity for all targets. “We are proud to extend the Elite InGenius respiratory menu, which now

FDA clears QuickVue Influenza A+B test

Feb. 27, 2018—Quidel announced it has received FDA 510(k) clearance for its CLIA-waived QuickVue Influenza A+B assay. The assay allows for the rapid, qualitative detection of influenza type A and type B antigens directly in nasal swab and nasopharyngeal swab specimens from symptomatic patients in approximately 10 minutes. In a clinical study, the QuickVue Influenza A+B test was shown to meet the FDA’s reclassification criteria for class II rapid influenza diagnostic tests. More top news

FDA clears Sebia Hydrashift 2/4 daratumumab assay

Feb. 26, 2018—Sebia announced it has received FDA 510(k) clearance for its Hydrashift 2/4 daratumumab assay, intended to be used with Hydragel IF, for the qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis. This in vitro diagnostic reagent mitigates the daratumumab-mediated interference seen in immunofixation results for patients with multiple myeloma treated with Darzalex (daratumumab), a fully human monoclonal antibody that binds to CD38. The assay was developed in collaboration with Janssen Biotech to provide the clinical

CAP TODAY webinar on influenza testing

Feb. 22, 2018—CAP TODAY is hosting a webinar titled “Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Compared with Reverse Transcriptase PCR” on Tuesday, Feb. 27, 1 PM ET. Presented by Jesse Papenburg, MD, MSc, FRCPC, and moderated by CAP TODAY publisher Bob McGonnagle, this hourlong webinar will empower you to understand new approaches to influenza testing and technologies, discover the key points of evaluation, and gain insight into the current field. Dr. Papenburg, FRQS clinical research scholar

Qiagen to buy Stat-Dx

Feb. 20, 2018—Qiagen has entered into an agreement to acquire Stat-Dx, a developer of molecular diagnostics systems, for $147 million. Once the transaction is completed, which is expected later this year, Qiagen will launch the QIAstat-Dx system, a next-generation, fully integrated multiplex platform for syndromic disease testing. QIAstat-Dx enables scalable sample-to-insight processing of up to 48 molecular targets simultaneously and can provide qualitative and quantitative insights in about one hour. The system, which is based on DiagCore technology, uses single-use

Qiagen launches Therascreen PITX2 test in Europe

Feb. 14, 2018—Qiagen announced the European launch of its novel Therascreen PITX2 RGQ PCR Kit, a clinically validated DNA methylation assay that helps predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy. The CE-IVD marked assay is Qiagen’s first epigenetic test in breast cancer. “We are very pleased to introduce this important test for personalized health care used to assess the best treatment approach for high-risk breast cancer patients. This reliable, clinically validated assay determines the PITX2

Inspirata buys digital pathology company Omnyx

Feb. 13, 2018—Inspirata, a biotechnology and software company, announced it has acquired Pittsburgh-based Omnyx from GE Healthcare. Omnyx’s flagship digital pathology software, Dynamyx, aims to enhance the pathology workflow by providing new channels for collaboration and tools to boost efficiency. The software is CE-marked in Europe and licensed by Health Canada for in vitro diagnostic use. “The acquisition of Omnyx positions Inspirata with the most comprehensive digital pathology workflow solution in the world,” Satish Sanan, CEO of Inspirata, said in

Alcor Scientific’s iSED at the Winter Olympics

Feb. 9, 2018—Alcor Scientific announced its iSED Analyzer will be used by the laboratory at the Korean Medicine Center at the Pyeongchang 2018 Olympic Winter Games and Paralympic Winter Games. The iSED is a fully automated erythrocyte sedimentation rate analyzer that analyzes red blood cells to diagnose bacterial infections and inflammation as well as to monitor patients’ responses to medications such as chemotherapy or steroids. It provides a result in 20 seconds. South Korea’s Ministry of Health and Welfare and

Advanced Instruments single-sample osmometer

Feb. 8, 2018—Advanced Instruments announced its Osmo1 Single-Sample Micro-Osmometer. It is suited for clinical laboratories that directly draw and test small sample volumes and was designed specifically to improve efficiency and reduce sample turnaround time. The instrument measures the osmolality of body fluids, such as whole blood, serum, plasma, urine, feces, sweat, and tissue homogenate, using the freezing point depression method, which provides results in 90 seconds. Only 20 μL of sample is needed. Features of the Osmo1 include an

MARKETPLACE

TRENDING